Celldex Seeks $90M, End Zone for Rindopepimut
By Marie Powers
Wednesday, February 6, 2013
Celldex Therapeutics Inc. upsized its underwritten public offering by pricing 12 million shares of common stock at $7.50 less than a 2 percent discount to Tuesday's close and a 1 percent premium to Monday's close to seek a $90 million raise rather than $75 million cited in a preliminary prospectus filed Monday with the SEC.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.